ArticleDiscover oncology2025
Mendelian randomization studies of gastric cancer reveal potential risk factors, promising biomarkers and therapeutic targets.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo further understand the causal relationship between potential risk factors or biomarkers and gastric cancer, we performed an extensive Mendelian randomization (MR) analysis.
methodsGenetic instruments were extracted from 486 available traits in 24 subcategories from the MR-Base platform, and ordinary two-sample MR, reverse MR, and mediating effect analyses were conducted based on 6563 gastric cancer cases and 195,745 controls from the BioBank Japan Project. We also performed Cox proportional hazards survival analysis, extensive phenotypic MR analysis, and molecular docking to evaluate potential biomarkers that may serve as therapeutic targets.
resultsFive identified risk factors were significantly associated with gastric cancer, including ulcerative colitis, vascular endothelial growth factor receptor 2 (VEGFR2), promotilin, neutrophil collagenase, and tyrosine-protein kinase receptor Tie-1 (soluble). The Cox proportional hazards survival analysis of the response genes KDR, MLN, MMP8, and TIE1 showed significant results in overall survival, first progression, and post-progression survival. The extensive phenotypic MR analysis found two associations with significant detrimental effects for targeting promotilin, including celiac disease and intestinal malabsorption (non-celiac), which showed beneficial effects for targeting neutrophil collagenase, and two associations with significant beneficial effects for targeting tyrosine-protein kinase receptor Tie-1, including hemorrhoids and functional digestive disorders. No significant associations were found for targeting VEGFR2. In addition, the results of chemotherapeutic sensitivity analysis and molecular docking of potential drugs with target genes also provide sufficient evidence for their important role in the treatment of gastric cancer.
conclusionIn conclusion, risk factor-associated genes KDR, MLN, MMP8, and TIE1 might be promising targets for the prevention and treatment of gastric cancer. These findings provide new insights into the causal factors of gastric cancer and new directions for the development of targeted therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.